ENLV
Enlivex Ltd.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
1.55
▲ 0.05 (3.33%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
1.49
Prev close
1.50
Day high
1.52
Day low
1.41
Volume
154.10K
Market cap
$25.70M
P/E (TTM)
0.00
52W range
1.39 – 27.15
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
12.40M
Total on file
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.50
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
7.50
+410.2% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
+421.9%
Puts bid over calls
Call volume
14
Contracts, this expiry
Put volume
7
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
2.50
12 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-6.96%
-5.6%
1M
-66.28%
-70.0%
3M
-86.39%
-89.5%
6M
-90.30%
-101.4%
YTD
-86.06%
-98.3%
1Y
-91.09%
-111.1%
3Y
-96.12%
-170.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$25.70M
Enterprise value$18.15M
Revenue (TTM)—
Gross profit—
EBITDA$-14.67M
Net income$1.24B
EPS (TTM)$382.20
Free cash flow$-1.74B
Total cash$5.75M
Total debt$641.00K
Book value / share$122.27
Shares outstanding17.49M
Float4.82M
Short % of float1.06%
Dividend yield—
Beta (5Y)1.47
Short interest
Shares short
177.54K
Prior 100.76K
Change vs prior
+76.2%
Shorts adding
% of float
1.06%
Normal
% of shares out
1.05%
Against total outstanding
Days to cover
0.6
Liquid
Float
4.82M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Valuation & profitability ratios
Trailing P/E0.00
Forward P/E-1.88
PEG ratio—
Price / sales—
Price / book0.01
EV / revenue—
EV / EBITDA-1.24
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity126.17%
Return on assets-0.80%
Debt / equity0.03
Current ratio193.24
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $9.20M | $10.62M | $19.01M | $18.69M | — | -13.4% |
| Selling, general & admin | $5.68M | $4.81M | $5.23M | $6.70M | — | +18.2% |
| Total operating expense | $15.00M | $14.93M | $25.15M | $25.80M | — | +0.5% |
| Operating income | -$15.00M | -$14.93M | -$25.15M | -$25.80M | — | -0.5% |
| Net interest income | $779.00K | $1.06M | $1.55M | $821.00K | — | -26.2% |
| Pre-tax income | $1.62B | -$15.01M | -$29.07M | -$31.06M | — | +10,877.8% |
| Tax provision | $382.65M | $0 | $0 | — | — | — |
| Net income | $1.24B | -$15.01M | -$29.07M | -$31.06M | — | +8,329.2% |
| Net income to common | $1.24B | -$15.01M | -$29.07M | -$31.06M | — | +8,329.2% |
| Basic EPS | — | -10.95 | -23.40 | -25.35 | -12.15 | — |
| Diluted EPS | — | -10.95 | -23.40 | -25.35 | -12.15 | — |
| EBIT | -$15.00M | -$14.93M | -$25.15M | -$25.80M | — | -0.5% |
| EBITDA | -$14.67M | -$14.39M | -$24.32M | -$25.02M | — | -2.0% |
| Basic shares | — | 1.37M | 1.24M | 1.23M | 1.19M | — |
| Diluted shares | — | 1.37M | 1.24M | 1.23M | 1.19M | — |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.89M | $3.30M | $813.00K | $49.95M | — | -42.6% |
| Cash & short-term investments | $5.75M | $23.50M | $27.32M | $50.24M | — | -75.5% |
| Accounts receivable | — | — | — | — | $2.20M | — |
| Total current assets | $1.74B | $25.99M | $33.76M | $52.33M | — | +6,606.3% |
| Property, plant & equipment | $938.00K | $1.15M | $2.58M | $14.90M | — | -18.6% |
| Total assets | $2.33B | $27.69M | $36.83M | $67.64M | — | +8,304.7% |
| Total current liabilities | $9.02M | $3.80M | $6.06M | $6.61M | — | +137.5% |
| Total debt | $641.00K | $534.00K | $1.03M | $4.85M | — | +20.0% |
| Total liabilities | $392.05M | $4.10M | $6.75M | $10.80M | — | +9,466.9% |
| Retained earnings | $1.11B | -$127.11M | -$112.09M | -$83.03M | — | +972.0% |
| Shareholder equity | $1.93B | $23.59M | $30.08M | $56.84M | — | +8,102.8% |
| Working capital | $1.73B | $22.19M | $27.70M | $45.72M | — | +7,713.6% |
| Net tangible assets | $1.93B | $23.59M | $30.08M | $56.84M | — | +8,102.8% |
| Shares issued | 15.83M | 1.58M | 1.24M | 1.23M | — | +903.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.24B | -$15.01M | -$29.07M | -$31.06M | +8,329.2% |
| Depreciation & amortisation | $332.00K | $545.00K | $835.00K | $777.00K | -39.1% |
| Stock-based compensation | $1.78M | $2.06M | $1.95M | $2.71M | -13.7% |
| Change in working capital | $815.00K | -$1.22M | -$1.82M | $804.00K | +166.9% |
| Operating cash flow | -$10.42M | -$13.01M | -$23.52M | -$23.95M | +19.9% |
| Capital expenditure | -$68.00K | -$103.00K | -$236.00K | -$8.12M | +34.0% |
| Investing cash flow | -$1.32M | $9.06M | -$25.97M | $62.52M | -114.6% |
| Financing cash flow | $10.38M | $6.45M | $360.00K | $150.00K | +60.8% |
| Free cash flow | -$10.48M | -$13.11M | -$23.76M | -$32.08M | +20.0% |
| End cash position | $2.37M | $3.73M | $1.23M | $50.36M | -36.4% |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $3.03M | $1.48M | $2.14M | $2.55M | $3.42M | +104.1% |
| Selling, general & admin | $2.72M | $1.07M | $937.00K | $954.00K | $1.96M | +153.6% |
| Total operating expense | $5.86M | $2.56M | $3.08M | $3.50M | $4.88M | +129.2% |
| Operating income | -$5.86M | -$2.56M | -$3.08M | -$3.50M | -$4.88M | -129.2% |
| Net interest income | -$864.00K | $352.00K | $1.21M | $81.00K | $638.00K | -345.5% |
| Pre-tax income | $1.63B | -$2.21M | -$1.87M | -$3.45M | -$5.18M | +73,827.8% |
| Net income | $1.24B | -$2.21M | -$1.87M | -$3.45M | -$5.18M | +56,474.3% |
| Net income to common | $1.24B | -$2.21M | -$1.87M | -$3.45M | -$5.18M | +56,474.3% |
| Basic EPS | — | -1.35 | -1.20 | -2.25 | — | — |
| Diluted EPS | — | -1.35 | -1.20 | -2.25 | — | — |
| EBIT | -$5.86M | -$2.56M | -$3.08M | -$3.50M | -$4.88M | -129.2% |
| EBITDA | -$5.79M | -$2.48M | -$2.99M | -$3.41M | -$4.84M | -133.6% |
| Basic shares | — | 1.60M | 1.59M | 1.58M | — | — |
| Diluted shares | — | 1.60M | 1.59M | 1.58M | — | — |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.89M | $4.08M | $1.89M | $2.05M | $3.30M | -53.6% |
| Cash & short-term investments | $5.75M | $18.20M | $19.51M | $20.55M | $23.50M | -68.4% |
| Total current assets | $1.74B | $19.50M | $21.32M | $22.65M | $25.99M | +8,840.3% |
| Property, plant & equipment | $938.00K | $1.08M | $923.00K | $1.07M | $1.15M | -13.2% |
| Total assets | $2.33B | $20.94M | $22.60M | $24.04M | $27.69M | +11,013.8% |
| Total current liabilities | $9.02M | $3.03M | $3.33M | $3.14M | $3.80M | +197.6% |
| Total debt | $641.00K | $701.00K | $480.00K | $503.00K | $534.00K | -8.6% |
| Total liabilities | $392.05M | $3.46M | $3.54M | $3.41M | $4.10M | +11,240.8% |
| Retained earnings | $1.11B | -$134.63M | -$132.43M | -$130.56M | -$127.11M | +923.3% |
| Shareholder equity | $1.93B | $17.48M | $19.05M | $20.63M | $23.59M | +10,968.9% |
| Working capital | $1.73B | $16.47M | $18.00M | $19.50M | $22.19M | +10,431.1% |
| Net tangible assets | $1.93B | $17.48M | $19.05M | $20.63M | $23.59M | +10,968.9% |
| Shares issued | 15.83M | 1.62M | 1.59M | 1.59M | 1.58M | +877.2% |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.24B | -$2.21M | -$1.87M | -$3.45M | -$5.18M | +56,474.3% |
| Depreciation & amortisation | $76.00K | $81.00K | $85.00K | $90.00K | $36.00K | -6.2% |
| Stock-based compensation | $915.00K | $280.00K | $295.00K | $293.00K | $917.00K | +226.8% |
| Change in working capital | $1.29M | -$176.00K | $172.00K | -$470.00K | $671.00K | +832.4% |
| Operating cash flow | -$2.63M | -$1.97M | -$1.20M | -$4.62M | -$4.08M | -33.4% |
| Capital expenditure | -$8.00K | -$21.00K | -$7.00K | -$32.00K | -$35.00K | +61.9% |
| Investing cash flow | -$9.38M | $3.81M | $1.07M | $3.17M | $3.36M | -345.9% |
| Financing cash flow | $9.83M | $352.00K | $0 | $197.00K | $1.26M | +2,693.2% |
| Free cash flow | -$2.63M | -$1.99M | -$1.21M | -$4.66M | -$4.12M | -32.4% |
| End cash position | $2.37M | $4.55M | $2.35M | $2.48M | $3.73M | -47.8% |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2025 | -0.45 | -1.41 | -212.7% |
| Sep 2025 | -1.80 | -1.35 | +25.0% |
| Jun 2025 | -2.40 | -1.20 | +50.0% |
| Mar 2025 | -2.40 | -2.25 | +6.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.31 | 1 | $0 | 0.0% |
| Next quarter | -0.31 | 1 | $0 | 0.0% |
| Current year | -1.15 | 1 | $0 | 0.0% |
| Next year | -0.21 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$80.00
High target$80.00
Low target$80.00
Implied upside5061.29%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders78.36%
Held by institutions1.62%
Institutions holding26
Price targets, consensus spread, insider and institutional ownership.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 7, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 12, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 24, 25 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Oct 29, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Sep 26, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Sep 12, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Sep 2, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 22, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Aug 18, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jul 29, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jul 22, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
Moving averages & technicals
SMA 10
1.68
-7.96% from price
SMA 20
2.01
-26.77% from price
SMA 50
5.28
-72.14% from price
SMA 100
8.74
-82.27% from price
SMA 200
11.94
-87.69% from price
EMA 12
1.84
-15.65% from price
EMA 26
2.90
-46.57% from price
EMA 50
4.86
-68.09% from price
RSI (14)
18.2
Oversold
MACD (12,26,9)
-1.06
Hist 0.18
ATR (14)
0.23
15.87% of price
Realised vol 30D
202.9%
Annualised
Bollinger upper
3.16
20, 2σ
Bollinger lower
0.86
20, 2σ
50 / 200 cross
Death
5.28 vs 11.94
Trend bias
Below 200
-87.69%
Risk profile
Beta vs SPY
1.29
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
202.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-91.9%
Peak to trough
Max drawdown 5Y
-99.3%
Peak to trough
ATR 14
0.23
15.87% of price
Beta (reported)
1.47
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateMar 6, 2019
Last split1:15
Split dateJul 9, 2026
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-08-11
Offering Registrations
F-3 · 2026-08-06
Corporate Changes & Voting Matters
6-K · 2026-07-30
Corporate Changes & Voting Matters
6-K · 2026-07-29
Corporate Changes & Voting Matters
6-K · 2026-07-28
Corporate Changes & Voting Matters
6-K · 2026-07-20
Corporate Changes & Voting Matters
6-K · 2026-07-13
Corporate Changes & Voting Matters
6-K · 2026-07-07
Headlines
Enlivex Shares Plunge After $400 Million Private Placement Deal
MT Newswires · 25d ago
Top Midday Decliners
MT Newswires · 25d ago
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
Zacks · 40d ago
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks · 40d ago
Enlivex's Allocetra Receives FDA RMAT Designation for Knee Osteoarthritis
MT Newswires · 40d ago
Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA
Investing.com · 40d ago
Enlivex Therapeutics Granted Patent in Australia for Allocetra to Treat Osteoarthritis
MT Newswires · 68d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.